查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1790419

美国肢端肥大症治疗市场规模、份额和趋势分析报告：按药物类别、分销管道和细分市场预测，2025-2033 年

U.S. Acromegaly Treatment Market Size, Share & Trends Analysis Report By Drug Class (Somatostatin Analogues, Growth Hormone Receptor Antagonists, Dopamine Agonists), By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国肢端肥大症治疗市场摘要

美国肢端肥大症治疗市场规模预计在 2024 年为 5.713 亿美元，预计到 2033 年将达到 9.772 亿美元，2025 年至 2033 年的复合年增长率为 6.2%。这是由于肢端肥大症的盛行率不断上升且诊断更为早期，再加上 MRI 和 IGF-1 检测等诊断工具的进步、认识的提高以及对疾病症状的更好理解。

诊断技术的进步和个人化治疗方法的采用有望促进早期发现和坚持治疗。强大的医疗基础设施、保险支援和多学科护理团队预计将进一步推动市场扩张。

此外，新型生长抑制素类似物、生长激素受体拮抗剂以及个人化治疗等治疗方案的进展，提高了疗效并减少了副作用。这些创新改善了患者的治疗效果，扩大了治疗范围，刺激了市场需求，并鼓励进一步的研发投入。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国肢端肥大症治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关市场展望
  • 产业价值链分析
  • 法律规范
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 产业挑战
    • 行业机会
  • 产业分析工具
    • 波特五力分析
  • 打入市场策略

第四章消费行为分析

  • 人口统计分析
  • 消费者趋势和偏好
  • 影响购买决策的因素
  • 消费者药品类别采用
  • 观察和建议

第五章美国肢端肥大症治疗市场：药物类别估计与趋势分析

  • 美国肢端肥大症治疗市场（按药物类别）的关键要点
  • 2024 年及 2033 年药品类别变化分析及市场占有率
  • 依药物类别，2021-2033 年
    • 生长抑制素类似物（SSA）
    • 生长激素受体拮抗剂（GHRAs）
    • 促效剂
    • 其他药物类型（联合治疗、在研药物）

第六章美国肢端肥大症治疗市场：通路评估与趋势分析

  • 美国肢端肥大症治疗市场的通路：关键要点
  • 2024年及2033年通路变化分析及市场占有率
  • 按分销管道划分，2021-2033 年
    • 医院药房
    • 零售药局
    • 其他的

第七章美国肢端肥大症治疗市场竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司热图/定位分析
  • 战略地图
  • 公司简介
    • Novartis AG
    • Ipsen Pharma
    • Sun Pharmaceutical Industries Ltd
    • Chiasma, Inc.
    • Crinetics Pharmaceuticals
    • WOCKHARDT
    • Pfizer Inc.
    • Ionis Pharmaceuticals, Inc.
    • Teva Pharmaceuticals
Product Code: GVR-4-68040-675-1

U.S. Acromegaly Treatment Market Summary

The U.S. acromegaly treatment market size was estimated at USD 571.3 million in 2024 and is projected to reach USD 977.2 million by 2033, growing at a CAGR of 6.2% from 2025 to 2033. This is attributed to the rising prevalence of acromegaly and earlier diagnoses, coupled with advancements in diagnostic tools such as MRI and IGF-1 tests, improved awareness, and a better understanding of the disease's symptoms.

Technological advances in diagnostics and the adoption of personalized treatment regimens are expected to help early detection and adherence. Strong healthcare infrastructure, insurance support, and multidisciplinary care teams are further expected to support market expansion.

Moreover, advances in treatment options, including newer somatostatin analogs, growth hormone receptor antagonists, and personalized therapies, offer improved efficacy and fewer side effects. These innovations enhance patient outcomes and expand the treatment pool, fueling market demand and encouraging further investment in research and development.

U.S. Acromegaly Treatment Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. acromegaly treatment market report based on drug class, and distribution channel:

  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Somatostatin Analogues (SSAs)
  • Growth Hormone Receptor Antagonists (GHRAs)
  • Dopamine Agonists
  • Other Drug Types (Combination Therapies, Pipeline Drugs)
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources & Third-Party Perspectives
    • 1.3.4. Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Data Visualization
  • 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Acromegaly Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related Market Outlook
  • 3.2. Industry Value Chain Analysis
  • 3.3. Regulatory Framework
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
    • 3.4.2. Market Restraint Analysis
    • 3.4.3. Industry Challenges
    • 3.4.4. Industry Opportunities
  • 3.5. Industry Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
  • 3.6. Market Entry Strategies

Chapter 4. Consumer Behavior Analysis

  • 4.1. Demographic Analysis
  • 4.2. Consumer Trends and Preferences
  • 4.3. Factors Affecting Buying Decision
  • 4.4. Consumer Drug Class Adoption
  • 4.5. Observations & Recommendations

Chapter 5. U.S. Acromegaly Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. U.S. Acromegaly Treatment Market Drug Class: Key Takeaways
  • 5.2. Drug Class Movement Analysis & Market Share, 2024 & 2033
  • 5.3. U.S. Acromegaly Treatment Market Estimates & Forecast, By Drug Class, 2021 To 2033 (USD Million)
    • 5.3.1. Somatostatin Analogues (SSAs)
      • 5.3.1.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
    • 5.3.2. Growth Hormone Receptor Antagonists (GHRAs)
      • 5.3.2.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
    • 5.3.3. Dopamine Agonists
      • 5.3.3.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
    • 5.3.4. Other Drug Types (Combination Therapies, Pipeline Drugs)
      • 5.3.4.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)

Chapter 6. U.S. Acromegaly Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. U.S. Acromegaly Treatment Market Distribution Channel: Key Takeaways
  • 6.2. Distribution Channel Movement Analysis & Market Share, 2024 & 2033
  • 6.3. U.S. Acromegaly Treatment Market Estimates & Forecast, By Distribution Channel, 2021 to 2033 (USD Million)
    • 6.3.1. Hospital Pharmacies
      • 6.3.1.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)
    • 6.3.2. Retail Pharmacies
      • 6.3.2.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)
    • 6.3.3. Others
      • 6.3.3.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)

Chapter 7. U.S. Acromegaly Treatment Market - Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Heat Map/ Positioning Analysis
  • 7.3. Strategy Mapping
  • 7.4. Company Profiles
    • 7.4.1. Novartis AG
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Ipsen Pharma
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Sun Pharmaceutical Industries Ltd
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Chiasma, Inc.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Crinetics Pharmaceuticals
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. WOCKHARDT
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Pfizer Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Ionis Pharmaceuticals, Inc.
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Teva Pharmaceuticals
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives

List of Tables

  • Table 1. U.S. Acromegaly Treatment Market Estimates And Forecast, By Drug Class, 2021 - 2033 (USD Million)
  • Table 2. U.S. Acromegaly Treatment Market Estimates And Forecast, By Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. Acromegaly Treatment Market Segmentation
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Primary Research Approaches
  • Fig. 5 Primary Research Process
  • Fig. 6 Market Snapshot
  • Fig. 7 Drug Class Segment Snapshot
  • Fig. 8 Distribution Channel Segment Snapshot
  • Fig. 9 Competitive Landscape Snapshot
  • Fig. 10 U.S. Acromegaly Treatment Market Value, 2024 (USD Million)
  • Fig. 11 U.S. Acromegaly Treatment Market - Industry Value Chain Analysis
  • Fig. 12 U.S. Acromegaly Treatment Market Dynamics
  • Fig. 13 U.S. Acromegaly Treatment Market: Porter's Analysis
  • Fig. 14 U.S. Acromegaly Treatment Market, By Drug Class: Key Takeaways
  • Fig. 15 U.S. Acromegaly Treatment Market, By Drug Class: Market Share, 2024 & 2033
  • Fig. 16 Somatostatin Analogues (SSAs) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Growth Hormone Receptor Antagonists (GHRAs) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Dopamine Agonists Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Other Drug Types (Combination Therapies, Pipeline Drugs) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 U.S. Acromegaly Treatment Market, By Distribution Channel: Key Takeaways
  • Fig. 21 U.S. Acromegaly Treatment Market, By Distribution Channel: Market Share, 2024 & 2033
  • Fig. 22 Hospital Pharmacies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Retail Pharmacies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Key Company Categorization
  • Fig. 26 Strategic Framework